Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
 reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Pages:
  • 1
  • 2
  • 3
  • CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2017]
    Learn More CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2017]
    Will CAR-T cell therapies shape the treatment of blood cancers in the next decade? Anti-CD19 CAR-T cell therapies have demonstrated unprecedented response rates across patient subgroups of acute lymphocytic leukaemia...
  • Nonalcoholic Steatohepatitis (NASH): KOL Insight [2017]
    Learn More Nonalcoholic Steatohepatitis (NASH): KOL Insight [2017]
    Will novel therapies revolutionise the treatment of NASH? No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but how is this set to change within the next five years?...
  •  Ovarian Cancer: KOL Insight [2017]
    Learn More Ovarian Cancer: KOL Insight [2017]
    How will new combination regimens impact the ovarian cancer treatment landscape? Competition is intensifying in the PARP inhibitor space due to the recent approval of Clovis’ Rubraca and Tesaro/Merck & Co...
  • Breast Cancer: KOL Insight [2017]
    Learn More Breast Cancer: KOL Insight [2017]
    How is Ibrance faring? Is Kisqali expected to be a threat? Having dominated the HER2-positive breast cancer space for many years, Roche’s blockbuster drug Herceptin is likely to face the threat of biosimilar...
  • COPD: KOL Insight [2017]
    Learn More COPD: KOL Insight [2017]
    Are closed triple combos expected to change treatment dynamics? New treatment guidelines look set to change the way in which COPD is treated. New guidelines from the Global Initiative for Chronic Obstructive Lung...
  • Rheumatoid Arthritis: KOL Insight [2017]
    Learn More Rheumatoid Arthritis: KOL Insight [2017]
    How are biosimilar anti-TNFs faring? Will your brand be affected? After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, it now looks like Eli...
  • Head and Neck Squamous Cell Cancer: KOL Insight [2017]
    Learn More Head and Neck Squamous Cell Cancer: KOL Insight [2017]
    How will immunotherapy continue to shape the HNSCC treatment landscape? The availability of Merck &Co.’s Keytruda and BMS’ Opdivo has already transformed the second-line treatment of head and neck...
  • Cystic Fibrosis: KOL Insight [2017]
    Learn More Cystic Fibrosis: KOL Insight [2017]
    How will the novel CFTR-function restoring therapies impact the CF landscape? The arrival of Vertex’s Kalydeco and Orkambi was a major advance in the disease-modifying CF therapy. However, despite their...
  • Acute Myeloid Leukaemia (AML): KOL Insight [2017]
    Learn More Acute Myeloid Leukaemia (AML): KOL Insight [2017]
    Will novel targeted therapies change AML treatment pathways?  For decades, chemotherapies have been at the forefront of AML treatment. How is this all set to change within the next few years? Novartis’...
  • Targeted Therapies in Asthma: KOL Insight (2017)
    Learn More Targeted Therapies in Asthma: KOL Insight (2017)
    Latest Update This edition presents key opinion leader (KOL) views on recent developments in the targeted asthma treatment market. Topics covered include; GlaxoSmithKline’s (GSK) presentation of new data at the...
  • Rheumatoid Arthritis: Payer Insight 2016
    Learn More Rheumatoid Arthritis: Payer Insight 2016
    Latest Update This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent biosimilar launches in the US such as Pfizer’s Inflectra (infliximab-dyyb) and...
  • Malignant Melanoma: KOL Insight 2016
    Learn More Malignant Melanoma: KOL Insight 2016
    New combinations emerging as immunotherapies become the backbone therapy Immunotherapies have become the go-to treatment for malignant melanoma, and with good reason. Not only are they proving to be the most effective...
  • Multiple Sclerosis: KOL Insight 2016
    Learn More Multiple Sclerosis: KOL Insight 2016
    Latest Update Gain new KOL insights on the latest events happening in multiple sclerosis (MS). Topics covered include; reactions to the latest safety and efficacy data for ibudilast (MediciNova) in progressive MS; the...
  • Ulcerative Colitis: KOL Insight 2016
    Learn More Ulcerative Colitis: KOL Insight 2016
    Latest Update Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on; Protagonist Therapeutics...
  • Colorectal Cancer: KOL Insight 2016
    Learn More Colorectal Cancer: KOL Insight 2016
    KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). Some say novel...
  • Type 2 Diabetes Mellitus: KOL Insight (2016)
    Learn More Type 2 Diabetes Mellitus: KOL Insight (2016)
    Can top-ranked GLP1 agonists move out of the third-line setting? GLP1 agonists may be the top-ranked type 2 diabetes mellitus (T2DM) treatment according to the American Association of Clinical Endocrinologists (AACE),...
  • Prostate Cancer: KOL Insight 2016
    Learn More Prostate Cancer: KOL Insight 2016
    Latest Update Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on the two oral PARP inhibitors (AstraZeneca’s Lynparza [olaparib]...
  • Chronic Lymphocytic Leukaemia: KOL Insight
    Learn More Chronic Lymphocytic Leukaemia: KOL Insight
    Latest Update Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of chronic lymphocytic leukaemia (CLL). Topics covered include several pieces of...
  • Non Small Cell Lung Cancer (NSCLC): KOL Insight
    Learn More Non Small Cell Lung Cancer (NSCLC): KOL Insight
    Latest Update Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including; the FDA accepting Merck and Co.’s regulatory filing for Keytruda (pembrolizumab) in combination...
  • Multiple Sclerosis: Payer Insight
    Learn More Multiple Sclerosis: Payer Insight
    Latest Update Topics covered in this update include: payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive...
  • Pages:
  • 1
  • 2
  • 3

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved